Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Mantle-Cell 3Lymphoma, Non-Hodgkin 2Pyloric Stenosis, Hypertrophic 1Lymphoma, Follicular 1Hematologic Neoplasms 1Hematologic Diseases 1

Interventions

Dexamethasone 3isatuximab 2Lenalidomide 2Cyclophosphamide 2pomalidomide 1fludarabine phosphate 1fludarabine 1daratumumab 1Watchful Waiting 1Vorinostat 1Vincristine 1Specimen Handling 1Rituximab 1Ranitidine 1R-CHOP protocol 1Prednisone 1Interviews as Topic 1Injections 1Histone Deacetylase Inhibitors 1Filgrastim 1Exercise 1Doxorubicin 1Diphenhydramine 1Data Collection 1Bortezomib 1Acetaminophen 1AC protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Hematologic Diseases × R-CHOP protocol × Clear all
NCT04243434 2020-04-16

PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients

Acrotech Biopharma Inc.

Phase 1 Unknown
56 enrolled
Other hematologic neoplasm

Hematologic Diseases, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡